Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy

PHASE3CompletedINTERVENTIONAL

Enrollment

718

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

November 30, 2003

Study Completion Date

April 30, 2004

Conditions

CancerNon-Myeloid Malignancies

Interventions

DRUG

rHuEPO

rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.

DRUG

Darbepoetin alfa

4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.